Ümide Demir Özkay1, Özgür Devrim Can2, Begüm Nurpelin Sağlık3, Nazlı Turan2. 1. Anadolu University, Faculty of Pharmacy, Department of Pharmacology, Eskişehir, Turkey. Electronic address: udemir@anadolu.edu.tr. 2. Anadolu University, Faculty of Pharmacy, Department of Pharmacology, Eskişehir, Turkey. 3. Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Eskişehir, Turkey.
Abstract
BACKGROUND: Acetylcholinesterase (AChE) inhibitors are frequently prescribed to mitigate the cognitive decline in Alzheimer's disease. Thus, we investigated the possible efficacy of the AChE inhibitor 2-[(6-Nitro-2-benzothiazolyl)amino]-2-oxoethyl4-[2-(N,N-dimethylamino)ethyl] piperazine-1 carbodithioate (BPCT) in a streptozotocin (STZ)-induced Alzheimer's disease model (SADM). METHODS: First, we analyzed the molecular interaction of BPCT with AChE via a docking study. Then, the cognitive effects of BPCT (10 and 20mg/kg) were evaluated in intracerebroventricular STZ- and vehicle-administered rats with the elevated plus maze (EPM), Morris water maze (MWM), and active avoidance (AA) tests. Locomotor activity was also assessed. RESULTS: Docking analysis indicated significant binding of BPCT to the AChE active site. In behavioral tests, STZ administration impaired cognitive performance in SADM rats versus control rats. Treatment with donepezil or BPCT significantly decreased the prolonged 2nd retention transfer latency and 2nd retention latency time values of the SADM group in the EPM and MWM tests, respectively. Further, prolonged latency times were decreased and reduced frequency of avoidance events were increased in the AA test. Locomotor activity between groups was not different. CONCLUSION: BPCT appears to function as a central AChE inhibitor, and its improvement of deficits in SADM rats suggests that it has therapeutic potential in Alzheimer's disease.
BACKGROUND:Acetylcholinesterase (AChE) inhibitors are frequently prescribed to mitigate the cognitive decline in Alzheimer's disease. Thus, we investigated the possible efficacy of the AChE inhibitor 2-[(6-Nitro-2-benzothiazolyl)amino]-2-oxoethyl4-[2-(N,N-dimethylamino)ethyl] piperazine-1 carbodithioate (BPCT) in a streptozotocin (STZ)-induced Alzheimer's disease model (SADM). METHODS: First, we analyzed the molecular interaction of BPCT with AChE via a docking study. Then, the cognitive effects of BPCT (10 and 20mg/kg) were evaluated in intracerebroventricular STZ- and vehicle-administered rats with the elevated plus maze (EPM), Morris water maze (MWM), and active avoidance (AA) tests. Locomotor activity was also assessed. RESULTS: Docking analysis indicated significant binding of BPCT to the AChE active site. In behavioral tests, STZ administration impaired cognitive performance in SADM rats versus control rats. Treatment with donepezil or BPCT significantly decreased the prolonged 2nd retention transfer latency and 2nd retention latency time values of the SADM group in the EPM and MWM tests, respectively. Further, prolonged latency times were decreased and reduced frequency of avoidance events were increased in the AA test. Locomotor activity between groups was not different. CONCLUSION:BPCT appears to function as a central AChE inhibitor, and its improvement of deficits in SADM rats suggests that it has therapeutic potential in Alzheimer's disease.
Authors: Mariana F B Gerzson; Natália P Bona; Mayara S P Soares; Fernanda C Teixeira; Francine L Rahmeier; Fabiano B Carvalho; Marilda da Cruz Fernandes; Giovana Onzi; Guido Lenz; Relber A Gonçales; Roselia M Spanevello; Francieli M Stefanello Journal: Neurotox Res Date: 2020-01-29 Impact factor: 3.911
Authors: Lorenz S Neuwirth; Michael T Verrengia; Zachary I Harikinish-Murrary; Jessica E Orens; Oscar E Lopez Journal: Front Mol Neurosci Date: 2022-08-17 Impact factor: 6.261
Authors: Mohamed R Aouad; Moataz A Soliman; Muath O Alharbi; Sanaa K Bardaweel; Pramod K Sahu; Adeeb A Ali; Mouslim Messali; Nadjet Rezki; Yaseen A Al-Soud Journal: Molecules Date: 2018-10-27 Impact factor: 4.411